French drugmaker Cellectis in sale talks -FT
May 28 (Reuters) - French cancer drugmaker Cellectis is in potential sale talks with a few suitors, including U.S. based Pfizer Inc (NYSE: PFE - news) , the Financial Times reported citing people familiar with the matter.
Although no outcome is certain of the talks, Pfizer, which already owns 9.47 percent of Cellectis, has approached it for a takeover, valuing it at 1.5 billion euros ($1.64 billion), FT said. (http://on.ft.com/1G3Z7hP)
Cellectis and Pfizer could not be immediately reached for comment.
In March, Cellectis listed itself on the Nasdaq raising $228 million through the sale of American Depository shares.
Cellectis, which works in the hot area of cancer immunotherapy, signed a deal with Pfizer last year to develop immunotherapy drugs.
($1 = 0.9135 euros) (Reporting by Ankush Sharma in Bangalore)